Back to results
US 12,679,869 B2Granted
Recombinant HIV Env polypeptides and their uses
AssigneesInternational AIDS Vaccine Initiative, The Scripps Research Institute
InventorsDennis R. Burton, Raiees Andrabi
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.
Claims19
An engineered or non-naturally occurring HIV Env polypeptide, wherein
- a) the engineered or non-naturally occurring HIV Env polypeptide is missing glycan sequons at N156 and N130 and has one or more basic residues at positions 168 to 171, wherein the HIV Env polypeptide;
- or
- b) the engineered or non-naturally occurring HIV Env polypeptide is an engineered or non-naturally occurring ZM233 HIV Env polypeptide missing glycan sequons at N156 and N130,
- wherein the HIV Env polypeptide positions correspond to the HXB2 reference (SEQ ID NO:
- 1).
2 more elements
A chimeric HIV Env polypeptide comprising an HIV Env polypeptide backbone and
- a) the V1V2 region of the ZM233 HIV Env polypeptide;
- or
- b) the amino acid residues of the ZM233 HIV Env polypeptide corresponding to positions about 131 to about 196, wherein the HIV Env polypeptide positions correspond to the HXB2 reference.
An HIV Env polypeptide comprising the amino acid sequence of SEQ ID NO:
- 6, 7, or 8.
Dependencies are inferred from the claim text.